Showing 3231-3240 of 5839 results for "".
- Get In First: A Derm's Case for Early Psoriasis Treatmenthttps://practicaldermatology.com/news/from-aad-2025-a-case-for-early-psoriasis-treatment/2471544/Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
- POETYK-PSO LTE: No New Safety Signals for Deucravacitinib at Five Yearshttps://practicaldermatology.com/news/poetyk-lte-no-new-safety-signals-for-deucravacitinib-at-five-years/2471170/Sotyktu (deucravacitinib) showed sustained efficacy and an acceptable safety profile over a period of 5 years in adults with moderate-to-severe plaque psoriasis, according to an announcement by Bristol Myers Squibb. Based on rec
- Analysis Finds 'Substantial' Links Between Nail PsO Lesions and Locationshttps://practicaldermatology.com/news/Analysis-Finds-Substantial-Links-Between-Nail-PsO-Lesions-Locations/2471103/A spatial relationship between onycholysis and oil spots, with the intra-nail location of onycholysis being more distal compared to the nearest oil spots, was one of the primary observations in a new analysis of nail psoriasis published in Annals of Dermatology. “Analysis of the Intra-Nail
- Analysis: Fibrosis Mechanisms in Systemic Sclerosis Skinhttps://practicaldermatology.com/news/fibrosis-mechanisms-ssc-skin/2470860/Researchers have identified a shift toward reticular gene expression in systemic sclerosis (SSc) skin, with disruptions in WNT/β-catenin signaling playing a key role in these changes. Authors for the study, published in Arthritis and Rheumatology, analyzed skin morphology and mole
- Study Explores 'Poppers Dermatitis' From Recreational Drugshttps://practicaldermatology.com/news/study-explores-poppers-dermatitis-recreational-drugs/2468371/Exposure to the chemicals in recreational drugs known as “poppers” could cause dermatitis, George Washington University researchers said in a press release about a study published in the Journal of the Drugs and Dermatology. Poppers are often used by gay men for their euphoric eff
- Analysis: Few Dermatologists Share Sun Protection Advice on TikTokhttps://practicaldermatology.com/news/analysis-few-dermatologists-share-sun-protection-advice-tiktok/2467072/A new analysis in the Journal of Drugs in Dermatology shows a significant gap in the presence of board-certified dermatologists (BCDs) on TikTok, particularly concerning sun protection content. "Limited studies have analyzed sources of TikTok videos associated with sun safety and
- Analysis: Deucravacitinib Shows Sustained Efficacy and Safety Over Four Yearshttps://practicaldermatology.com/news/analysis-deucravacitinib-shows-sustained-efficacy-and-safety-over-four-years/2466961/A new analysis suggested that deucravacitinib showed acceptable safety and efficacy over the course of 4 years of treatment. The POETYK PSO-1 and PSO-2 trials, upon which the analysis was based, randomized patients in (1:2:1) to receive placebo, deucravacitinib 6 mg once daily (QD), or a
- Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and AD in Four Additional Countrieshttps://practicaldermatology.com/news/galderma-receives-filing-acceptances-nemolizumab-prurigo-nodularis-and-ad-four-additional-countries/2462968/
- FRONTIER-2: Novel Oral Peptide Maintains Safety, Efficacy Out to 1 Yearhttps://practicaldermatology.com/news/frontier-2-novel-il-23-targting-oral-peptide-maintains-safety-efficacy-out-to-1-year/2462424/A targeted oral peptide targeting interleukin-23 (IL-23) was associated with high rates of clearance and consistent safety through 1 year of treatment in adults with moderate-to-severe plaque psoriasis, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in
- Important FDA Approvals in 2023 Lead to New, Exciting Treatments in 2024https://practicaldermatology.com/news/important-fda-approvals-in-2023-lead-to-new-exciting-treatments-in-2024/2462219/A slew of big approvals for new therapies in 2023 has increased the armamentarium for dermatologists treating many conditions going into 2024, according to an opening presentation at Maui Derm 2024. <